Compare PRAX & SIRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | SIRI |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 7.3B |
| IPO Year | 2020 | 1996 |
| Metric | PRAX | SIRI |
|---|---|---|
| Price | $292.00 | $22.03 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 8 |
| Target Price | ★ $572.13 | $25.00 |
| AVG Volume (30 Days) | 321.1K | ★ 3.4M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.86% |
| EPS Growth | N/A | ★ 136.32 |
| EPS | N/A | ★ 2.23 |
| Revenue | N/A | ★ $5,425,129,000.00 |
| Revenue This Year | N/A | $1.81 |
| Revenue Next Year | $6,395.88 | $0.65 |
| P/E Ratio | ★ N/A | $9.97 |
| Revenue Growth | N/A | ★ 8.13 |
| 52 Week Low | $26.70 | $18.69 |
| 52 Week High | $354.87 | $24.55 |
| Indicator | PRAX | SIRI |
|---|---|---|
| Relative Strength Index (RSI) | 37.08 | 55.10 |
| Support Level | $290.36 | $22.02 |
| Resistance Level | $322.32 | $22.54 |
| Average True Range (ATR) | 17.42 | 0.53 |
| MACD | -5.25 | 0.01 |
| Stochastic Oscillator | 7.97 | 59.95 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
SiriusXM operates almost exclusively in the US through its SiriusXM and Pandora audio services. SiriusXM is primarily a satellite radio service that offers nationwide coverage and mostly ad-free listening, with proprietary channels and exclusive content. It makes agreements with automakers to install its radios in vehicles and give trial services to vehicle buyers, which have traditionally fed its subscriber base. The company provides the service via a fleet of geostationary satellites it owns and operates, and now offers a streaming SiriusXM option. Pandora, which accounts for a much smaller portion of revenue and profit, offers a subscription and ad-supported streaming music service that competes with industry giants such as Spotify, Apple Music, and YouTube Music.